GoldenGolden
Advanced Search
Adimab

Adimab

Adimab is a company focused on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience, and pain.

Adimab is an industry leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, and translating target hypotheses into therapeutically relevant antibody drugs. Adimab has started more than 360 antibody discovery campaigns with more than eighty partners, which range from top academic institutions to top pharma companies.

The company focuses on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience and pain. The Adimab platform is based on synthetic and natural immune repertoires, which are propagated and screened in its proprietary yeast system. Its technology allows selecting key antibody properties in real time.

Its primary discovery process has the goal of offering a diverse panel of fully human antibodies tailored to target product profile. The goal of primary discovery is to find the most diverse panel of leads to comprehensively interrogate the target biology people are hoping to modulate.

Timeline

April 2, 2012
Adimab raises a $13,800,000 series F round from Borealis Ventures, Google Ventures, OrbiMed Advisors, Polaris Partners and SV Health Investors.
January 22, 2010
Adimab raises a $8,200,000 series D round from Borealis Ventures and Polaris Partners.
November 20, 2008
Adimab raises a $4,000,000 series C round from Borealis Ventures and Polaris Partners.
April 1, 2008
Adimab raises a $3,180,000 series B round.
September 21, 2007
Adimab raises a $5,900,000 series A round from Polaris Partners.

Funding rounds

People

Name
Role
LinkedIn

Alison Stace-Naughton

Employee

Errik Anderson

Founder

Georges Harik

Investor

John Platts

Investor

Jonathan Belk Ph.D.

Employee

Krishna Yeshwant

Investor

Phil Ferneau

Investor

Shervin Ghaemmaghami

Investor

Tim Dybvig

Employee

Further reading

Title
Author
Link
Type
Date

Case study on Adimab

Axial

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
July 16, 2020
FierceBiotech
Coronaviruses have jumped from animals to humans before--and they'll do it again. That's why Adagio Therapeutics is working on antibodies that can fight multiple members of the virus family, including SARS-CoV-2, the culprit behind the current pandemic. The startup snagged $50 million to push its lead candidates into the clinic.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.